

# Daniel Palmer

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6202249/daniel-palmer-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25  
papers

1,975  
citations

18  
h-index

26  
g-index

26  
ext. papers

2,191  
ext. citations

10.7  
avg, IF

4.02  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 25 | High-resolution crystal structure of human protease-activated receptor 1. <i>Nature</i> , <b>2012</b> , 492, 387-92  | 50.4 | 353       |
| 24 | TMEM16F forms a Ca <sup>2+</sup> -activated cation channel required for lipid scrambling in platelets during blood coagulation. <i>Cell</i> , <b>2012</b> , 151, 111-22  | 56.2 | 292       |
| 23 | Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 1871-9   | 15.9 | 272       |
| 22 | Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. <i>Molecular Pharmacology</i> , <b>2003</b> , 64, 533-46  | 4.3  | 260       |
| 21 | The sphingosine 1-phosphate receptor S1P <sub>1</sub> maintains the homeostasis of germinal center B cells and promotes niche confinement. <i>Nature Immunology</i> , <b>2011</b> , 12, 672-80   | 19.1 | 184       |
| 20 | Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. <i>Circulation Research</i> , <b>1998</b> , 82, 852-61  | 15.7 | 78        |
| 19 | Wnt/ $\beta$ -catenin signaling is differentially regulated by G $\beta$ proteins and contributes to fibrous dysplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 20101-6  | 11.5 | 71        |
| 18 | Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 26615-24 | 5.4  | 64        |
| 17 | Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. <i>Molecular Pharmacology</i> , <b>2000</b> , 58, 247-52  | 4.3  | 54        |
| 16 | Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. <i>British Journal of Pharmacology</i> , <b>1997</b> , 122, 233-40  | 8.6  | 48        |
| 15 | Neutrophil depletion decreases VEGF-induced focal angiogenesis in the mature mouse brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2007</b> , 27, 1853-60   | 7.3  | 48        |
| 14 | Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 18605-10  | 11.5 | 38        |
| 13 | Bone marrow-derived cells contribute to vascular endothelial growth factor-induced angiogenesis in the adult mouse brain by supplying matrix metalloproteinase-9. <i>Stroke</i> , <b>2011</b> , 42, 453-8  | 6.7  | 37        |
| 12 | Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 9411-9419  | 5.4  | 36        |
| 11 | MC4R Agonists: Structural Overview on Antiobesity Therapeutics. <i>Trends in Pharmacological Sciences</i> , <b>2018</b> , 39, 402-423  | 13.2 | 31        |
| 10 | Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. <i>Molecular Pharmacology</i> , <b>2002</b> , 61, 1033-40   | 4.3  | 31        |
| 9  | Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 2563-9  | 9.4  | 26        |

|   |   |     |    |
|---|---|-----|----|
| 8 | Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. <i>Diabetes</i> , <b>2002</b> , 51, 1194-200 | 0.9 | 26 |
| 7 | Click-Chemistry-Mediated Synthesis of Selective Melanocortin Receptor 4 Agonists. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 8716-8730   | 8.3 | 15 |
| 6 | Identification of a novel scaffold for a small molecule GPR139 receptor agonist. <i>Scientific Reports</i> , <b>2019</b> , 9, 3802  | 4.9 | 6  |
| 5 | C-Terminal lactamization of peptides. <i>Chemical Communications</i> , <b>2021</b> , 57, 895-898  | 5.8 | 3  |
| 4 | Design and Combinatorial Development of Shield-1 Peptide Mimetics Binding to Destabilized FKBP12. <i>ACS Combinatorial Science</i> , <b>2020</b> , 22, 156-164  | 3.9 | 2  |
| 3 | MC4R as a Target for Pharmacotherapeutic Treatment of Obesity and Type 2 Diabetes <b>2020</b> , 935-946   |     |    |
| 2 | Inhibition of the ADP/P2Y12 Pathway Confers Additional Protection against Arterial Thrombosis in PAR-4 Deficient Mice. <i>Blood</i> , <b>2008</b> , 112, 3933-3933  | 2.2 |    |
| 1 | Comparative studies of adhesion peptides based on l- or d-amino acids. <i>Journal of Peptide Science</i> , <b>2016</b> , 22, 642-646  | 2.1 |    |